@article{oai:nagasaki-u.repo.nii.ac.jp:00027351,
 author = {Hara, Kazusato and Umeda, Masataka and Segawa, Keiko and Akagi, Midori and Endo, Yushiro and Koga, Tomohiro and Kawashiri, Shin-ya and Ichinose, Kunihiro and Nakamura, Hideki and Maeda, Takahiro and Kawakami, Atsushi},
 issue = {8},
 journal = {Internal medicine},
 month = {Apr},
 note = {A 49-year-old Japanese man with a 2-month history of a fever, headache, and bilateral conjunctival hyperemia was admitted. His condition fulfilled the giant cell arteritis classification criteria (new headache, temporal artery tenderness, elevated ESR) and atypical Cogan’s syndrome (CS) with scleritis and sensorineural hearing loss (SNHL). The interleukin (IL)-6 serum level was extremely high. Two weeks after his insufficient response of SNHL and scleritis to oral prednisolone, we administered tocilizumab (TCZ); rapid improvements in scleritis and SNHL occurred. Early IL-6 target therapy can help prevent irreversible CS-induced sensory organ damage., Internal medicine, 61(8), pp1265-1270; 2022},
 pages = {1265--1270},
 title = {Atypical Cogan’s Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab},
 volume = {61},
 year = {2022}
}